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FROM THE EDITOR

Action Items for Breast Cancer Awareness Month
Deanna J. Attai, MD | Issue Editor (Women and Cancer)
Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA

October is Breast Cancer Awareness Month (BCAM) in
many countries, and it’s hard to miss it. Pink merchandise
floods the stores, all types of products are labeled with
pink ribbons, and countless stories are told of women
who have “beat” breast cancer. Often, the messaging
is focused on early detection and the importance of
screening mammograms.
This special issue of the Journal of Patient-Centered
Research and Reviews is dedicated to the theme “Women
and Cancer.” In addition to containing original research
on uterine cancer, hysterectomy, and pain relief during
labor,1-3 several articles published within this issue
pertain to predicting treatment outcomes, improving
quality of life, and gleaning the patient perspective of
those affected by breast cancer.4-8 These impactful studies
are the kind that demand further support, both in terms of
patient participation and research funding, and it’s time
for awareness campaigns to drive the public toward such
new and promising goals.
Herein, we briefly describe the origination of marketing
campaigns aimed at increasing breast cancer awareness
and how these campaigns could be updated to avoid
losing relevance to a present-day public already educated
on the importance of screening.
History of the Pink Ribbon

The pink ribbon that has adorned everything from National
Football League player uniforms to bags of pet food actually
started off as a peach-colored ribbon. The message that
Charlotte Haley wanted to send in 1992 was one of lack of
research funding for cancer prevention. When she declined
to allow her ribbon to be used for a magazine marketing
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campaign, a pink ribbon was
used instead.9,10 Since that
time, breast cancer advocacy
organizations
are
often
distinguished by pink logos
and use the ribbon in their
educational and marketing
materials. Many wear pink
to signify their struggles with
the disease or to show support
for a loved one who has been
treated for breast cancer.
However, the pink ribbons are not always appreciated.
Some people with breast cancer do not feel comfortable
being “branded” or identified by their medical condition,
and many patients do not identify with the term
“survivor,”11 which is often used in BCAM campaigns.
Men and the impact of male breast cancer are often left
out of BCAM messaging. In addition, concerns have been
raised regarding “pinkwashing,” when a pink ribbon and
inspiring slogan are placed on a product with a message
of awareness, even though no proceeds from the sale of
the product actually go toward breast cancer education,
detection, or research.12
The reality of breast cancer is that the patient experience
does not always fit neatly into a positive or inspirational
marketing campaign. Efforts to raise awareness of breast
cancer risk factors, benefits of screening, and treatment
options remain necessary. However, there are important
aspects of breast cancer not being addressed at many
of the attention-grabbing pink ribbon events, including
metastatic breast cancer, male breast cancer, and racial
and ethnic disparities related to diagnosis, treatment,
and outcomes. Thus the question is raised: Is spreading
awareness enough, and do existing advocacy campaigns
accurately reflect the many faces of breast cancer?
Metastatic Breast Cancer

The traditional messaging that “early detection saves
lives” does not always hold true — early detection is
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important, but it is not the only factor that impacts survival.
Metastatic breast cancer occurs when the original tumor
has spread beyond the breast and regional lymph nodes,
most commonly to the lungs, liver, bone, and brain.13 It
is estimated that there are approximately 150,000 women
in the United States currently living with metastatic
breast cancer. However, U.S. registries do not routinely
collect or report recurrence data, so more precise figures
are not available.14,15 Metastases are more likely to occur
in the setting of higher stage at diagnosis or aggressive
tumor biology but can occur even in those diagnosed
with early stage, slower growing tumors, including after
a long disease-free interval. Approximately 6% of all
newly diagnosed breast cancers are de novo metastatic,
meaning they are metastatic at the time of diagnosis.16 The
American Cancer Society estimates that approximately
41,000 women and 500 men in the United States will die
this year due to breast cancer,16 with most of these deaths
caused by metastatic breast cancer. Death from breast
cancer certainly does not fit into the “survivor” narrative,
and patients with metastatic breast cancer are often left
out of awareness campaigns. In 2009, the U.S. Congress
did designate October 13 as National Metastatic Breast
Cancer Awareness Day.17
Metastatic breast cancer can develop in those who
have been adherent to recommended screening and
therapy, essentially having “done everything right.”
While treatments continue to advance and many with
metastatic disease are experiencing improved survival
rates compared with years past, there is no cure. The
fact is, we do not always understand why some patients
develop metastatic cancer and some do not, or why some
metastatic cancers progress despite modern therapy and
some are controlled. This knowledge gap could be closed
sooner if all breast cancer advocacy groups devoted more
of their time, platform, and resources toward metastatic
research efforts. As one advocacy organization asserts in
its tagline, these patients are “dying for a cure.”18

to educate the public about presenting signs and
symptoms, treatment options, and the association of male
breast cancer with pathogenic genetic mutations (eg,
BRCA mutations). This is slowly changing, in part due to
media attention when a male celebrity is diagnosed21 and
the tireless work of patient advocacy groups. The Male
Breast Cancer Coalition series titled “Men Have Breasts
Too” features patient stories from men diagnosed with
breast cancer,22 which can serve as a source of education
and support for men diagnosed with what is typically
considered a “female” disease.
Inclusion of men in clinical trials is an important and
essential step to help determine the best treatment
approach for male breast cancer. The U.S. Food and Drug
Administration (FDA) has recently recommended that
men be included in clinical trials evaluating medications
for the treatment of breast cancer, specifically noting
that the “FDA does not intend to consider low expected
accrual rates of male patients with breast cancer to be a
sufficient scientific rationale for excluding them from a
clinical trial.”23 An ongoing international multicenter
collaboration should provide important insights into the
biologic differences between breast cancer in men and
women, as well as draw attention to the unique physical
and psychological effects experienced by men diagnosed
with and treated for breast cancer.19,24
Men must be included in advocacy and awareness
campaigns with a focus on presenting symptoms,
treatment options, the role of family history and genetic
testing, and the unique supportive care needs of men.
Disparities

Male Breast Cancer

Not all patient populations have benefited from
improvements in cancer screening, treatment, and
outcomes. Disparities exist and may be related to race
or ethnicity, socioeconomic status, sexual orientation,
gender identity, and other factors.25,26 Costs of care,
including nonmedical costs such as transportation, may
disproportionately affect certain patient populations.27,28

Despite this disease burden, men are not commonly
featured in awareness campaigns, missing an opportunity

Importantly, not all disparities can be adequately
explained by imbalanced societal structures, health care
barriers and biases, or simple awareness. Breast cancer
is less common in Black women compared with White
women, but Black women have poorer outcomes, in part
due to later stage and younger age at diagnosis, as well
as higher likelihood of diagnosis with the triple-negative
subtype. Biological differences in breast cancers in Black
compared with White women have been identified,
although more research is needed to determine the impact
of biological versus socioeconomic factors associated
with delays in diagnosis and higher mortality rates.29-31

Male breast cancer accounts for approximately 1% of
all breast cancers. This small percentage presents a
challenge, as the relative infrequency of breast cancer
occurring in men contributes to limited awareness and
lack of inclusion in many clinical trials. Men are more
likely to be diagnosed at later stages, and their outcomes
are poorer compared with women diagnosed at the same
stage. Treatment for male breast cancer usually follows
established protocols for breast cancer treatment in
women, despite lack of evidence in some situations.19,20
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While there are a growing number of advocacy groups
specifically focused on minority patient populations and
their unique needs, large national advocacy organizations
should take the lead to ensure that their awareness
campaigns and support programs also address these
issues. The American Society of Clinical Oncology has
recently updated its policy statement on cancer disparities
and health equity with specific recommendations to
promote health equity by focusing on access to highquality care, improving clinical research, and addressing
structural barriers.25,26
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